A Call to Action to Overcome Obstacles in the Optimal Testing and Treatment of FLT3-Mutated AML

Achieve a deeper understanding of the biologic rationale for using FLT3 inhibitors in the management of FLT3-mutated acute myeloid leukemia to personalize treatment plans and optimize patient outcomes through certified text modules, an expert-written ClinicalThought commentary, and downloadable slides.

Share

Program Content

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc.